Nordic Nanovector 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Alf Bjornseth

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	4.5yrs
이사회 평균 재임 기간	8.2yrs

최근 관리 업데이트

Recent updates

CEO

Alf Bjornseth

less than a year

테뉴어

Mr. Alf Bjornseth is Chief Executive Officer of Nordic Nanovector ASA from June 28, 2023.

리더십 팀

이름	위치	테뉴어	보상	소유권
Alf Bjornseth	Chief Executive Officer	less than a year	데이터 없음	데이터 없음
Fredrik Haavind	Head of Legal & Compliance	4.3yrs	데이터 없음	데이터 없음
Maureen Deehan	Head of Corporate Development & Strategy	5.1yrs	데이터 없음	데이터 없음
Reza Safaei	Head of Medical Affairs	5.9yrs	데이터 없음	데이터 없음
Mark Wright	Head of Manufacturing	4.5yrs	데이터 없음	데이터 없음

4.5yrs

평균 재임 기간

경험이 풍부한 관리: NANOV 의 관리팀은 경험 ( 4.5 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Mark Kaminski	Member of Scientific Advisory Board & Member of Clinical Advisory Board	no data	데이터 없음	데이터 없음
Lorenz Trümper	Member of Scientific Advisory Board	8.2yrs	데이터 없음	데이터 없음
Stephen Schuster	Member of Scientific Advisory Board	8.2yrs	데이터 없음	데이터 없음
Ludvik Sandnes	Chairman	less than a year	NOK 372.00k	데이터 없음
Timothy Illidge	Chairman of Scientific Advisory Board	8.2yrs	데이터 없음	데이터 없음
Pier Zinzani	Chairman of Scientific Advisory Board	8.2yrs	데이터 없음	데이터 없음
Arne Kolstad	Member of Scientific Advisory Board	8.2yrs	데이터 없음	데이터 없음
Francesco D'Amore	Member of Scientific Advisory Board	8.2yrs	데이터 없음	데이터 없음
Wojciech Jurczak	Member of Scientific Advisory Board	8.2yrs	데이터 없음	데이터 없음
Jon Asmyr	Director	less than a year	데이터 없음	3.58% NOK 8.3m
Tina Bonsdorff	Director	less than a year	데이터 없음	데이터 없음

8.2yrs

평균 재임 기간

경험이 풍부한 이사회: NANOV 의 이사회는 경험(평균 재직 기간 8.2 년)으로 간주됩니다.

Nordic Nanovector 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Nordic Nanovector ASA Approves the Appointment of Ludvik Sandnes as New Chairman

Nordic Nanovector ASA Announces Resignation of Jostein Dahle, Chief Scientific Officer and Co-Founder

Chairperson recently bought kr436k worth of stock

Nordic Nanovector ASA Announces CFO Changes

Nordic Nanovector ASA Announces Resignation of Eddie Berglund from the Board Effect from January 19, 2023

No independent directors

Recent updates

Nordic Nanovector ASA Approves the Appointment of Ludvik Sandnes as New Chairman

Nordic Nanovector ASA Announces Resignation of Jostein Dahle, Chief Scientific Officer and Co-Founder

Chairperson recently bought kr436k worth of stock

New major risk - Share price stability

Nordic Nanovector ASA Announces CFO Changes

Nordic Nanovector ASA Announces Resignation of Eddie Berglund from the Board Effect from January 19, 2023

No independent directors

Nordic Nanovector ASA Approves Board Changes

Nordic Nanovector ASA to Report First Half, 2023 Results on Aug 31, 2023

Nordic Nanovector ASA (OB:NANOV) agreed to acquire 100% stake in APIM Therapeutics AS from Sarsia Seed AS, Trond Mohn Stiftelsen, Norsk Innovasjonskapital (NIK) III Fund, and Investinor Direkte AS.

Nordic Nanovector ASA Announces Resignation of Solveig Hellebust, Jean Pierre Bizzari and Thomas Ramdahl from the Board

Can Nordic Nanovector (OB:NANOV) Afford To Invest In Growth?

Nordic Nanovector ASA Announces Executive Changes

Nordic Nanovector ASA to Report Q2, 2022 Results on Aug 31, 2022

Nordic Nanovector to Seek Regulatory Feedback Following Its Preliminary Review and Independent Data Evaluation of Paradigme, Its Phase 2B Trial with Betalutin in R/R Follicular Lymphoma

Nordic Nanovector ASA Provides an Update on PARADIGME, Its Phase 2b trial of Betalutin in R/R FL as a Result of Continuing Slow Recruitment

Nordic Nanovector ASA Publishes Highlights Synergistic Potential of CD37-Targeted Radioimmunoconjugate Humalutin

Price target decreased to kr26.00

Price target decreased to kr26.00

Insufficient new directors

Price target increased to kr31.00

Nordic Nanovector ASA Provides an Update on the Timeline for PARADIGME

Is Nordic Nanovector (OB:NANOV) In A Good Position To Invest In Growth?

Price target decreased to kr27.25

Nordic Nanovector ASA Provides Update on Paradigme, Its Phase 2B Pivotal Trial with Betalutin® in R/R Follicular Lymphoma

Chief Executive Officer Peter Braun has left the company

We Think Nordic Nanovector (OB:NANOV) Needs To Drive Business Growth Carefully

Nordic Nanovector Announces Initial Results from LYMRIT 37-05 Phase 1 Trial of Betalutin® in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Nordic Nanovector ASA Announces Update from Archer-1 Phase 1B Trial of Betalutin® in Combination with Rituximab in 2L Follicular Lymphoma

Independent Director has left the company

Nordic Nanovector ASA Appoints Peter L. Braun as Chief Executive Officer, Effective 6 April 2021

Price target raised to kr28.25

Nordic Nanovector ASA Sees Significant Improvement in Patient Recruitment Rate in PARADIGME, its Single-Arm Phase 2 Pivotal Trial with Betalutin in R/R Follicular Lymphoma

New 90-day high: kr20.00

Nordic Nanovector ASA to Report Fiscal Year 2020 Results on Mar 27, 2021

Is Nordic Nanovector (OB:NANOV) In A Good Position To Invest In Growth?

Nordic Nanovector ASA to Report Q2, 2021 Results on Aug 27, 2021

Nordic Nanovector ASA Completes Patient Enrolment into Phase 1 Trial of Betalutin® in Diffuse Large B Cell Lymphoma

Price target lowered to kr21.00

Price target lowered to kr38.50

Nordic Nanovector ASA Completes Enrolment into Second Safety Cohort of Follicular Lymphoma Patients in Archer-1 Phase 1B Betalutin®/Rituximab Combination Trial

New 90-day low: kr14.85

Nordic Nanovector Asa Publishes Results of Preclinical Study Demonstrating Betalutin Reverses Tumour Resistance to Rituximab in NHL Disease Models

New 90-day low: kr16.83

Nordic Nanovector Launches A -2-Haematogical L Cancers

New 90-day high - kr27.90

CEO

테뉴어

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간